A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
To compare the efficacy and safety of recombinant humanized anti-VEGF monoclonal antibody (601) with Ranibizumab in patients with macular edema secondary to BRVO
Epistemonikos ID: c37ee15cbfcb0dd15798cfce2b562e1d8076f8b9
First added on: May 13, 2024